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The Changing Microbial Environment and Chronic
Inflammatory Disorders
Graham A.W. Rook, BA, MB, BChir, MD
There is much to be gained from examining human diseases within the expanding framework of Darwinian medicine. This is
particularly true of those conditions that change in frequency as populations develop from the human ‘‘environment of evolutionary
adaptedness’’ to the living conditions of the rich industrialized countries. This development entails major changes in lifestyle, leading
to reductions in contact with environmental microorganisms and helminths that have evolved a physiologic role as drivers of
immunoregulatory circuits. It is suggested that a deficit in immunoregulation in rich countries is contributing not only to increases in
the incidence of allergic disorders but also to increases in other chronic inflammatory conditions that are exacerbated by a failure to
terminate inappropriate inflammatory reponses. These include autoimmunity, neuroinflammatory disorders, atherosclerosis,
depression associated with raised inflammatory cytokines, and some cancers.
I
n 1989, Strachan showed that in young adults, a history
of hay fever was inversely related to the number of
children in the family when the subject was 11-years old.
1
Further studies suggested that having many siblings,
especially older ones, correlated with diminished risk of
hay fever, and these findings were considered consistent
with a protective influence of postnatal infection, which
might be lost in the presence of modern hygiene.
2 So the
‘‘hygiene hypothesis’’ was born. The concept was initially
vague and lacked mechanistic explanations, so in the 28
years since the original study, a multitude of different,
often mutually exclusive, versions of this hypothesis have
been considered. Often this has led to the ‘‘disproving’’ of
hypotheses that few had intended to propose in the first
place. However, during the last 9 years, an essentially new
hypothesis has emerged, which we have preferred to
designate ‘‘the old friends hypothesis.’’ This hypothesis
might not be relevant to Strachan’s original findings,
which remain unexplained, but it does have very broad
importance for understanding the influence of changing
patterns of microbial exposure on trends in human disease
and is leading to encouraging clinical trials. Moreover, the
old friends hypothesis belongs within the rapidly growing
framework of ‘‘evolutionary medicine,’’ which seeks to
clarify our understanding of disease by considering our
evolutionary history.
This review first outlines various ‘‘failed’’ versions of
the hygiene hypothesis and then describes the old friends
hypothesis and its implications not only for allergic
disorders but also for other chronic inflammatory
disorders, such as autoimmunity and inflammatory bowel
disease (IBD). Finally, evidence is tentatively outlined
suggesting that the concept might be relevant to other
disorders in which proinflammatory cytokines play a
major role, such as the metabolic syndrome, atherosclero-
sis, depression, and some types of neurodegeneration.
Failed Hypotheses
Childhood Infections
Strachan’s studies pointed to the possibility that the
common infections of childhood might protect children
from allergic disorders. Many allergologists found this
view difficult to accept because allergies are rife in the
inner cities of rich countries, where these infections are
particularly common. More importantly, excellent studies
have indicated that these infections do not protect children
from allergies.
3 Most strikingly, children in daycare centres
do not have an increased risk of atopy if they wash more
often and reduce their infection rate. Thus, prevention of
common respiratory tract and enteric infections during
early childhood does not change later allergic morbidity.
4
It now seems likely that Strachan’s original findings were
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infection during the period in which the sibings studied
were born.
1 HAV binds to lymphocytes via a receptor that
modulates the development of T-cell subsets.
5 Thus, it is
part of the hygiene hypothesis but rather separate from the
main theme of this review.
Domestic Hygiene
A second, partially overlapping view, largely created by
journalists attracted to the word hygiene, was that home
hygiene itself was to blame. Newspaper articles implied
that we should avoid hygienic practices such as the use of
bactericidal products, and interviewers tried to make
scientists advise listeners to let their children live in
squalor. Again, a detailed recent report rejected this
simplistic concept.
6 The history of the major changes in
hygiene practices shows that they did not occur at the right
times to correlate with increases in the incidence of
allergies.
6
T Helper 1/T Helper 2 Balance or Effector/Regulator
Balance?
Although these hypotheses were failing, the suggested
mechanism was overproduction of T helper 2 (Th)2 cells
as a consequence of diminished infections and consequent
diminished production of Th1 cells. According to this
interpretation, the critical issue was Th1/Th2 balance, but
this was never a strong hypothesis. First, Th1 cytokines
such as interferon-c (IFN-c) are present in large quanitites
in both asthma
7 and established atopic dermatitis.
8
Second, profound defects in the interleukin (IL)-12 or
IFN-c (Th1) pathways do not lead to an increased
incidence or severity of allergic disorders, implying that
in humans Th1 is not a physiologic regulator of Th2
responses.
9 Finally, the Th1/Th2 balance hypothesis has
been untenable since as early as 1998,
10 by which time, it
had been well documented that there was a simultaneous
increase in Th1-mediated chronic inflammatory diseases
(type 1 diabetes, multiple sclerosis, inflammatory bowel
disease),
11 occurring in the same countries as the increases
in allergic disorders.
12 Moreover, individuals infected by
helminths, which enhance Th2 responses, are paradoxically
less likely to have allergic sensitization or allergic disorders,
and treating the infection leads to increased allergic
sensitization.
13
These points all suggested that the critical problem was
not Th1/Th2 balance but rather a broad and increasing
failure in the rich developed countries of immunoregula-
tory mechanisms that should terminate inappropriate
inflammatory responses, whether Th1 or Th2 and whether
targeting allergens or self (autoimmunity) or gut contents
(IBD). This is now the prevailing view.
Balance of Effector to Regulatory T Cells
In support of this concept, immunoregulation has been
shown to be faulty in individuals suffering from allergic
disorders
14 and some autoimmune diseases,
15,16 and
probably in IBD too.
17,18 A striking example in auto-
immunity is a recent experiment of nature.
19 Patients in
Argentina suffering from multiple sclerosis were followed
up for 4.6 years. It was found that those who developed
parasite infections (which were not treated) had signifi-
cantly fewer exacerbations than those who did not.
Moreover, they also developed regulatory T cells (Tregs)
(CD4
+, CD25hi, Foxp3
+), which specifically responded to
myelin basic protein. In other words, the presence of the
parasite appeared to drive the development of Tregs that
recognized the autoantigen and inhibited the disease
process.
It is clear that a failure of immunoregulatory mechan-
isms can indeed lead to simultaneous increases in diverse
types of pathology because genetic defects of Foxp3, a
transcription factor that plays a crucial role in the
development and function of Tregs, leads to a syndrome
known as X-linked autoimmunity–allergic dysregulation
syndrome (XLAAD), which includes aspects of allergy,
autoimmunity, and enteropathy.
20
Old Friends Hypothesis
Rather than focusing on the common infections of
childhood, the old friends hypothesis draws on epidemio-
logic studies demonstrating that protection from allergies
is associated with living in developing countries and with
the farming environment.
21,22 These observations have
been repeated many times in different environments and
appear solid. Humans evolved in a hunter-gatherer
environment, which is regarded as our environment of
evolutionary adaptedness.
23 Much subsequent human
evolution has been cultural rather than genetic.
Nevertheless, the development of farming about 10,000
years ago led to a dramatic change in humans’ microbial
environment and to a further series of genetic adaptations.
The intervening <500 generations are sufficient to have
allowed major changes in gene frequencies. For example,
farmers needed to be able to digest the lactose in milk from
domesticated animals, and the frequency of relevant
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than 90% in many populations.
24
Against this background, the old friends hypothesis
suggests that the lack of appropriate levels of immunor-
egulatory pathways in rich northern countries is a
consequence of diminished exposure to two categories of
organism. First, harmless organisms associated with mud,
untreated water, and fermenting vegetable matter were
present throughout mammalian evolution but are greatly
diminished in a world of concrete, treated water, and
washed vegetables. These organisms include various
Lactobacillus strains, saprophytic mycobacteria, other
actinomycetes, and, no doubt, many other genera.
Second, helminthic infections, always present in humans’
progenitors but possibly increased in variety and load
when animal husbandry began, are still common in
developing countries but almost completely absent
from rich ones.
25 The former needed to be tolerated
because they were harmless but always present in large
numbers in food and water. The helminthic parasites
needed to be tolerated because, although not always
harmless, once they were established in the host, any effort
by the immune system to eliminate them was likely to
cause tissue damage. For instance, a futile effort to destroy
Brugia malayi microfilariae resulted in lymphatic blockage
and elephantiasis.
26
A cartoon of the pathway by which these organisms are
currently thought to prime immunoregulation and
mediate protection from allergies, autoimmunity, and
IBD is shown in Figure 1. The host-parasite relationship
evolved so that rather than provoking needless, damaging,
aggressive immune responses, these organisms cause a
pattern of maturation of dendritic cells (DCs) such
that these drive Tregs rather than Th1 or Th2 effector
cells.
27,28 This, in turn, leads to two mechanisms that
help control inappropriate inflammation. First, the con-
stitutive presence of the old friends causes continuous
background activation of the dendritic regulatory cells
(DCregs) and of Tregs specific for the old friends
themselves, resulting in constant background bystander
suppression of inflammatory responses. Second, these
DCregs inevitably sample self and gut contents and
allergens and so induce Tregs specific for the illicit target
antigens of the three groups of chronic inflammatory
disorder. These inhibitory mechanisms are aborted when
there are legitimate ‘‘danger’’ signals.
29
Figure 1. Organisms such as helminths and environmental saprophytes, which are part of mammalian evolutionary history (‘‘old friends’’) and
must be tolerated, are detected by pattern recognition receptors such as Toll-like receptor 2 (TLR2) and CARD15 (caspase recruitment domain
family, member 15) on dendritic cells (DCs). The DCs mature into regulatory DCs that drive regulatory T cell (Treg) responses to the antigens of
these organisms. The continuing presence of these antigens in the gut flora, in food, or resident as parasites such as microfilariae leads to
continuous background release of regulatory cytokines from these Tregs, exerting bystander suppression of other responses, as shown in the upper
arm of the figure. Meanwhile, the increased numbers of regulatory DCs lead to increased processing by such DCs of self-antigens, gut content
antigens, and allergens, as shown in the lower arm of the figure. Therefore, the numbers of Tregs specifically triggered by these antigens is also
increased, downregulating autoimmunity, inflammatory bowel disease, and allergies, respectively. CTLA-4 5 cytotoxic T-lymphocyte antigen 4;
IL-10 5 interleukin-10; TGF-b 5 transforming growth factor b.
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clinical trials and experimental models in which exposure
to microorganisms that were ubiquitous during mamma-
lian evolutionary history but are currently ‘‘missing’’ from
the environment in rich countries (or from animal units
with specific pathogen-free facilities) will treat allergy,
30–32
autoimmunity,
33 or intestinal inflammation.
34
We do not understand all of the ways in which DCregs
and Tregs evoked by the old friends block or terminate
inflammatory responses. However, we know that the release
of the anti-inflammatory cytokines IL-10 and transforming
growth factor (TGF)-b is often involved.
30,31 The next
sections summarize the evidence that a relative lack of Tregs
and DCregs, leading secondarily to a decrease in immuno-
regulation and a decrease in these anti-inflammatory
mediators, might be contributing to the increases in a wide
variety of disorders in the developed countries (Figure 2).
IL-10-Dependent Disorders
In addition to the allergic disorders, autoimmunity, and
IBD, all of which have been considered in detail in relation
to the old friends hypothesis in the past,
11,25 several other
disorders are also increasing and are likely to be
exacerbated or made more common by a switch in the
balance of inflammatory to anti-inflammatory mechan-
isms (see Figure 2).
Atherosclerosis
The metabolic syndrome, which involves abdominal
obesity, hypertriglyceridemia, low high-density lipoprotein
cholesterol, and insulin resistance, has risen to a prevalence
of 41% in New York.
35 It has been observed recently that
whereas women with uncomplicated obesity have
increased serum levels of IL-10, those with the metabolic
syndrome do not.
36 Could this imply less regulatory cell
activity? The hypothesis is strengthened by considering
atherosclerosis, which is a T cell–mediated inflammatory
lesion in blood vessel walls and is considerably more
common in patients with the metabolic syndrome.
Atherosclerotic plaques are inflammatory lesions dri-
ven mostly by Th1 cells.
37 Several independent groups
have found that IL-10 and TGF-b have a downregulatory
Figure 2. Human physiology was shaped by the hunter-gatherer way of life, which is regarded as the human ‘‘environment of evolutionary
adaptedness,’’ although there have been further adaptations during the approximately 10,000 years (<500 generations) since the introduction of
farming and livestock. Most human evolution has been cultural and technological rather than genetic, and a gene-environment misfit may be
occurring. Harmless organisms that were abundant in food and water (such as environmental actinomycetes) and helminths that had to be
tolerated developed a role in the induction of immunoregulatory circuits. Without these, there may be a failure to terminate inappropriate
inflammatory responses, leading to an increased susceptibility to chronic inflammatory disorders, the precise nature of which depends on the
genetics and history of the individual. DCreg 5 dendritic regulatory cells; Th 5 T helper; Treg 5 regulatory T cells.
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37
Atherosclerosis is exaggerated in IL-10-deficient mice.
38 By
contrast, mice with transgenic T cells overexpressing IL-10
are protected from atherosclerosis,
39 and in several
experimental models, transfer of Tregs will also inhibit
atherosclerosis.
40 Infection with Schistosoma mansoni
inhibits atherogenesis in mice, and although the authors
attributed this to effects on lipid metabolism, induction of
Tregs is likely.
41 Further evidence was reviewed by Kuiper
and colleagues.
42
There is similar evidence that IL-10 has a beneficial role
in human atherosclerotic plaques,
37,43–45 and serum levels
of IL-10 are reduced in patients with unstable angina.
46
Interestingly, atherosclerotic lesions contain a very low
percentage of Tregs as determined by direct immunohis-
tochemistry.
47
Alzheimer Disease
The neurodegenerative disorders Alzheimer disease (AD)
and Parkinson disease (PD) both appear to be mediated by
inflammation.
48 This is apparent from both the pathol-
ogy
48 and the epidemiology. Japanese American men in
Honolulu were examined 25 years after a blood sample was
taken to measure C-reactive protein (CRP), using very
sensitive assays.
49 Raised CRP was associated with a higher
incidence of AD and vascular dementia 25 years later. As
mentioned earlier, the metab o l i cs y n d r o m ei si t s e l f
associated with inflammatory cytokines, and a study in
the United States yielded support for the hypothesis that
the metabolic syndrome contributes to eventual cognitive
impairment in the elderly, particularly in those with a high
serum CRP and IL-6.
50 Other studies have yielded
preliminary evidence that AD is associated with single
nucleotide polymorphisms (SNPs) that lead to increased
production of IL-6
51 or tumor necrosis factor (TNF).
52
Moreover, a large meta-analysis concluded that prolonged
intake of nonsteroidal anti-inflammatory drugs can give
some protection against AD.
53,54
There is also some evidence that the neurodegenerative
conditions are more common in individuals with SNPs of
their IL-10 genes that modulate production of this
cytokine. For instance, in an Italian population, the
presence of the 21082A allele was proposed as a genetic
risk factor for AD.
55 Other studies found similar associa-
tions, although not always with the same allele or
haplotype,
51,56,57 and a study based in Germany found
no associations at all,
58 so the matter remains unre-
solved.
54 The role of IL-10 is equally unclear in relation to
PD. IL-10 SNPs were not related to sporadic PD in a Polish
population,
59 but a Swedish study that documented the
21082A/G SNP found that the age at onset of PD was
delayed by 5 years in individuals with two G alleles
compared with individuals with two A alleles.
60
Meanwhile, there is accumulating evidence that TGF-b
might have anti-AD effects both because of its immuno-
regulatory and anti-inflammatory properties and because
it enhances clearance of amyloid-b.
54
Depression and Anxiety
Some stress-related psychiatric conditions, particularly
depression and anxiety, are associated with markers of
ongoing inflammation, even in the absence of any
accompanying inflammatory disorder.
61 Thus, depressed
subjects may have raised proinflammatory cytokines and
evidence of an ongoing acute-phase response. Moreover,
proinflammatory cytokines can induce depression, which is
commonly seen in patients with cancer or hepatitis when
they are treated with IL-2 or IFN-c.I nt h e s ep a t i e n t s ,b r a i n
imaging shows a pattern similar to that which accompanies
spontaneously occurring depression, and the depression can
be treated with paroxetine, a serotonin reuptake inhibitor
antidepressant.
62 Similarly, there is evidence that depression
can be associated with polymorphisms that lead to the
overproduction of proinflammatory cytokines,
63 whereas in
sharp contrast, treatmentsthatneutralizethese cytokinescan
alleviate depression.
64 Therefore, some psychiatric disorders
in developed countries might be attributable to failure of
immunoregulatory circuits to terminate ongoing inflamma-
tory responses, leading to prolonged ‘‘sickness behaviour’’
andmoodchanges. Thisviewisfurthersupportedbythefact
that depression is associated with low expression of TGF-b
and IL-10 relative to expression of proinflammatory
cytokines.
65,66 Moreover, antidepressants increase secretion
of IL-10.
67
Recently, unexpected improvements in mood were
observed during clinical trials with an immunomodulatory
vaccine that induces Tregs. This led to an investigation of
this material in a mouse model and to the discovery that it
activates a specific group of brain serotoninergic neurons
involved in the pathophysiology of mood disorders and
exerts a fluoxetine hydrochloride (Prozac)-like effect in an
industry standard test for antidepressant activity.
68 This
area has now been reviewed in depth.
69
Cancer
Chronic inflammatory lesions, such as those induced by
chronic infections (viruses, Chlamydia, or bacteria),
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associated with increased cancer risk.
70 This is partly
because inflammatory mediators are involved in control of
cell replication, angiogenesis, and cell migration and also
drive increased levels of reactive oxygen intermediates that
can cause deoxyribonucleic acid (DNA) damage.
70 Many
of these functions of inflammation are regulated by the
transcription factor nuclear factor k (NF-kB), and
manipulating the activity of NF-kB has profound effects
on tumorigenesis.
71 Interestingly, TNF-a
2/2 or TNF
receptor 1
2/2 mice are more resistant to chemically
induced carcinogenesis.
70,72 Similarly, several SNPs of
chemokines and cytokines are associated with malig-
nancy.
70 Conversely, anti-inflammatory drugs may be
protective. Regular input of nonsteroidal anti-inflamma-
tory drugs, such as aspirin, that inhibit cyclooxygenase-2
(the inducible form of prostaglandin H synthase) is
associated with reduced risk of colorectal cancer.
73
Esophageal cancer provides a vivid example of the role
of inflammation; reflux of gastric acid, alcohol, and
tobacco all predispose individuals to esophageal cancer.
74
Clearly, this is a complex issue where cancer is
concerned. It is reasonable to suggest that failing
immunoregulation might allow chronic inflammation
and so predispose individuals to carcinogenesis. On the
other hand, excessively effective immunoregulation might
impede the immune system’s attempts to destroy cancer
cells once the cancer is established.
75 Nevertheless, a
proinflammatory haplotype of SNPs in IL-6, IL-10, and
TNF-a is associated with a poor prognosis in gastro-
esophageal malignancy,
76 and it is clear that the inflam-
matory response can provide mediators that assist the
growth and spread of the cancer.
70 Thus, diminished
background immunoregulation in rich countries, as
explained by the old friends hypothesis, might explain
some of the increase in certain cancers.
Conclusions
The original hygiene hypothesis gave rise to several daughter
hypotheses, all of which lacked epidemiologic and historical
credibility, as outlined above. This review attempts to show
how a broader view, focusing on major changes in lifestyle
that accompany the shift from hunter-gatherer to indus-
trializedsociety, passing via herding and farming, can leadto
a hypothesis that falls within Darwinian medicine and has
considerable explanatory power. It is clear that multiple
environmental changes must contribute to changing pat-
terns of disease, and this brief overview does not intend to
imply that diminished input of Treg-inducing organisms
such as helminths and harmless environmental saprophytes
is the only factor. There are numerous other ways in which
harmless microorganisms or infections can influence health.
For example, changes in bowel flora secondary to dietary
changes will play a role, and obesity itself increases
inflammatory cytokine levels. Similarly, urbanization led to
increased incidences of diseases such as tuberculosis, and
selection of genetic variants confering resistance to such
infections might lead to increased susceptibility to auto-
immunity. This review therefore covers only one subset of
the relevant mechanisms and emphasizes our increasing
awareness of humans’ place within the evolutionary frame-
work of the biosphere. This must be considered in the light
of humans’ unique ability to change their environment by
means of technology, with little accompanying adaptive
genetic change. Therefore, it is logical to explore the
possibilityofagene-environmentmisfit,leadingtoincreased
susceptibility to chronic inflammatory disorders. The list of
disorders discussed here in this context is illustrative, and
many others might need to be added.
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